Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?

Title:Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?

Volume: 22 Issue: 10

Author(s): Sarubala Malayaperumal, Sushmitha Sriramulu, Antara Banerjee, M.K. Makalakshmi and Surajit Pathak*

Affiliation:

• Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Chennai 603103, Tamil Nadu,India

Keywords: Conventional, therapeutics, colon cancer, overall survival, chemoradiotherapy, personalized medicine.

Abstract:

Background: Colon cancer is the second leading cause of cancer related deaths worldwide with about 1.2 million new cases identified annually. While considering swift progress in the field of molecular biology, new horizons in the treatment approaches have been materialized in colon cancer with conventional methods being replaced with targeted therapies.

Methods: In this review, we focused on the existing conventional therapies utilized for colon cancer by comparing the effectiveness of various standard/conventional therapies with respect to overall survival parameter. Regardless of all the conventional treatments and scientific research, the disease remains to be the one of the major cause of cancer related death and rising as societal burden due to its co morbidities. Thus, we have also discussed briefly in this review, all the possible biotechnological next-generation therapeutics including nucleic acid medicines, CRISPR-Cas9 technology, adoptive cell therapy, cancer stem cells and therapy, gut microbiome, and personalized medicines, which might be promising after effective clinical trials.

Results: From our study, we suggest that the use of neoadjuvant chemoradiotherapy in resected patients was found to be safe and effective therapy in treating colon cancer and thereby improving overall survival in patients. From considering the total estimate of our meta-analysis plot, we state that the existing therapies are not much satisfying to improve the overall survival and more research has to be carried out in this field to find an effective therapy to treat colon cancer.

Conclusions: As existing therapies are not much satisfying and are unable to improve the overall survival, we brought together a diversity of possible approaches focusing on biotechnological nextgeneration therapeutics to treat colon cancer. Hence, various multi-disciplinary choices are mandatory in order to provide patients with distended access to tailored treatments.

Cite this article as:

Malayaperumal Sarubala , Sriramulu Sushmitha , Banerjee Antara , Makalakshmi M.K. and Pathak Surajit *, Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?, Current Pharmaceutical Biotechnology 2021; 22 (10) . https://dx.doi.org/10.2174/1389201021666201126142716